Abstract
Dendritic cells (DC), capable of activating naïve T cell population and of inducing primary immune responses, play an important role as the most potent antigen-presenting cells. Recently, it has been possible to generate large quantities of mature DCin vitroand to pulse them with a variety of antigens. This study is focused on investigation the priming ability of murine bone marrow dendritic cells (BMDC) loaded either with tumour lysates of the HPV 16-induced carcinoma MK 1612stably producing E7 and activatedrasoncoproteins or with the HPV 16 E7 peptide RAHYNIVTF. Moreover, the priming capacity BMDC and two established lines of dendritic cells, DC2.4 and JAWS II, were compared
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Smahel, M., Sobotková, E., Bubeník, J., Símová, J., 2ák, R., Ludvíková, V., Hájková, R., Kovarik, J., Jelínek, F., Povÿsil, C., Marinov, J. and Vonka, V., in press, Metastatic MHC class I negative mouse cells derived by transformation with human papillomaviruses type 16: A model for studies on vaccination against papillomavirus-associated tumours..Brit. J. Cancer.
Bubeník, J, Símová, J., Hájková, R., Sobota, V., Jandlová T, Smahel, M., Sobotková, E., Vonka, V., 1999, Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.Int J Oncol14: 593–597.
Shen, Z., Reznikoff, G., Dranoff, G., Rock, K.L., 1997, Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.J. Immunol.158: 2723–2730.
Mendoza, L., Indrová, M., Hájková, R., Reinis, M., Smahel, M., Vonka, V., Bubeník, J., Jandlová, T., 2000, Peritumoral administration of antigen-unstimulated bone marrow-derived dendritic cells inhibits tumour growth.Folia Biol (Praha)46: 91–97.
Indrová, M.., Bubenik, J., Símová, J., Vonka, V., N¨¨mei ková, S., Mendoza, L., Reinil, M., 2001, Therapy of HPV 16-associated carcinoma with dendritic cell-based vaccines:In vitropriming of the effector cell responses by DC pulsed with tumour lysates and synthetic RAHYNIVTF peptide.Int. J.Molec. Med.7: 97–100.
Bubeník, J., Indrová, M., Mme¨®ková, S, Malkovskÿ, M., von Broen, B., Pálek, V., Anderlíková, J., 1978, Solubilized tumour-associated antigens of methylcholanthreneinduced mouse sarcomas. Comparative studies by in vitro sensitization of lymph node cells, macrophage electrophoretic mobility assay and transplantation tests.Int J Cancer21: 348–355.
Bubenik, J., Símová, J., Vonka, V., Smahel, M., Mikysková, R., Mendoza, L., in press, Dendritic cell-based vaccines for therapy of HPV 16-induced tumours.Adv. Exp Med. Biol.this issue.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Indrová, M. et al. (2001). Bone marrow dendritic cell-based anticancer vaccines. In: Mackiewicz, A., Kurpisz, M., Żeromski, J. (eds) Progress in Basic and Clinical Immunology. Advances in Experimental Medicine and Biology, vol 495. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0685-0_50
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0685-0_50
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5194-8
Online ISBN: 978-1-4615-0685-0
eBook Packages: Springer Book Archive